ProKidney Webcast Details Rilparencel Mechanism in Advanced Chronic Kidney Disease

ProKidney Corp. held a webcast on October 27, 2026, with CEO Bruce Culleton and R&D head Anthony Conway discussing rilparencel's mechanism and its potential role in advanced chronic kidney disease. The company said its aim is to extend life without dialysis for patients with advanced CKD, Seeking Alpha reported.

What ProKidney Said About Rilparencel

Prokidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy intended to preserve kidney function in advanced CKD patients with type 2 diabetes. The therapy is in Phase 3 trials, with pivotal results expected in Q2 2027.

Culleton opened the webcast by describing the company's mission. "At ProKidney, our mission is to transform the outlook for people with advanced chronic kidney disease by extending life without dialysis," he said. He said the discussion would focus on the science supporting the company's work and rilparencel's potential role.

Ethan Holdaway, vice president of strategic finance and investor relations, introduced the webcast as an American Society of Nephrology Kidney Week recap and corporate update. Holdaway said a replay would be made available on the ProKidney website after the event. Joining Culleton and Conway was Katherine Tuttle, executive director for research at Providence Inland Northwest Health and professor of medicine at the University of Washington.

ProKidney's Cash and Enrollment Position

According to akta.pro company records, ProKidney reported $181.6 million in cash, cash equivalents and marketable securities as of Q2 2026, down from $224.9 million in Q1 2026, with cash runway into mid-2027. The same records show Q2 2026 revenue of $150,000, a decline from $221,000 in the prior year period.

The records also show ProKidney completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis in August 2026, positioning the company for pivotal eGFR slope topline results in Q2 2027.

ProKidney's Path to the PROACT 1 Readout

ProKidney reported Q1 2026 results with $224.9 million in cash and a $42.6 million net loss, and said it expected to complete Phase 3 PROACT 1 enrollment in mid-2026 and deliver pivotal topline results in Q2 2027, BioSpace reported.

In August 2026, ProKidney reported Q2 2026 results, completing enrollment for the accelerated approval efficacy analysis of PROACT 1, with pivotal eGFR slope topline results anticipated in Q2 2027 and full enrollment expected in H2 2026, Stock Titan reported.

ProKidney's Next Data Readout

ProKidney has said pivotal eGFR slope topline results from the PROACT 1 accelerated approval efficacy analysis are anticipated in Q2 2027, and full enrollment in the study is expected in H2 2026.